Total Payments
$260,479
2024 Payments
$23,412
Companies
16
Transactions
309
Medicare Patients
502
Medicare Billing
$76,916
Payment Breakdown by Category
Other$158,988 (61.0%)
Consulting$58,569 (22.5%)
Travel$32,623 (12.5%)
Food & Beverage$7,373 (2.8%)
Research$2,788 (1.1%)
Education$137.49 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $156,938 | 54 | 60.2% |
| Consulting Fee | $58,569 | 11 | 22.5% |
| Travel and Lodging | $32,623 | 93 | 12.5% |
| Food and Beverage | $7,373 | 131 | 2.8% |
| Unspecified | $2,788 | 16 | 1.1% |
| Honoraria | $2,050 | 2 | 0.8% |
| Education | $137.49 | 2 | 0.1% |
Payments by Type
General
$257,690
293 transactions
Research
$2,788
16 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Biogen, Inc. | $124,230 | 89 | $0 (2020) |
| GENZYME CORPORATION | $53,280 | 86 | $0 (2024) |
| EMD Serono, Inc. | $23,621 | 38 | $0 (2020) |
| Celgene Corporation | $16,255 | 23 | $0 (2024) |
| Amgen Inc. | $10,992 | 12 | $0 (2024) |
| Roche Products Limited | $9,632 | 4 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $6,000 | 5 | $0 (2022) |
| Alexion Pharmaceuticals, Inc. | $5,487 | 12 | $0 (2019) |
| Greenwich Biosciences, Inc. | $3,808 | 1 | $0 (2021) |
| SANOFI US SERVICES INC. | $2,788 | 16 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $23,412 | 33 | Amgen Inc. ($10,870) |
| 2023 | $2,073 | 3 | Horizon Therapeutics plc ($2,073) |
| 2022 | $3,600 | 3 | E.R. Squibb & Sons, L.L.C. ($3,600) |
| 2021 | $8,368 | 6 | Greenwich Biosciences, Inc. ($3,808) |
| 2020 | $30,703 | 43 | Biogen, Inc. ($15,547) |
| 2019 | $81,327 | 90 | Biogen, Inc. ($40,975) |
| 2018 | $67,665 | 77 | Biogen, Inc. ($41,330) |
| 2017 | $43,331 | 54 | Biogen, Inc. ($26,378) |
All Payment Transactions
309 individual payment records from CMS Open Payments — Page 1 of 13
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Amgen Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,650.00 | General |
| 11/12/2024 | Amgen Inc. | UPLIZNA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,300.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 10/30/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $124.83 | General |
| Category: Inflammation/Rare Disease | ||||||
| 06/25/2024 | Roche Products Limited | — | Travel and Lodging | Cash or cash equivalent | $8,966.54 | General |
| 06/25/2024 | Roche Products Limited | — | Travel and Lodging | Cash or cash equivalent | $401.15 | General |
| 06/25/2024 | Roche Products Limited | — | Food and Beverage | In-kind items and services | $135.15 | General |
| 06/25/2024 | Roche Products Limited | — | Travel and Lodging | Cash or cash equivalent | $129.14 | General |
| 06/03/2024 | Amgen Inc. | UPLIZNA (Biological) | Travel and Lodging | Cash or cash equivalent | $125.52 | General |
| Category: Inflammation/Rare Disease | ||||||
| 06/03/2024 | Amgen Inc. | UPLIZNA (Biological) | Travel and Lodging | Cash or cash equivalent | $87.50 | General |
| Category: Inflammation/Rare Disease | ||||||
| 06/03/2024 | Amgen Inc. | UPLIZNA (Biological) | Travel and Lodging | Cash or cash equivalent | $29.48 | General |
| Category: Inflammation/Rare Disease | ||||||
| 05/13/2024 | Amgen Inc. | UPLIZNA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,300.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 05/13/2024 | Amgen Inc. | UPLIZNA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,100.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 05/03/2024 | Amgen Inc. | UPLIZNA (Biological) | Travel and Lodging | In-kind items and services | $388.36 | General |
| Category: Inflammation/Rare Disease | ||||||
| 05/01/2024 | Amgen Inc. | UPLIZNA (Biological) | Travel and Lodging | In-kind items and services | $375.99 | General |
| Category: Inflammation/Rare Disease | ||||||
| 04/16/2024 | Amgen Inc. | UPLIZNA (Biological) | Travel and Lodging | In-kind items and services | $388.36 | General |
| Category: Inflammation/Rare Disease | ||||||
| 03/21/2024 | SANOFI US SERVICES INC. | — | — | Cash or cash equivalent | $72.00 | Research |
| Study: A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | ||||||
| 03/21/2024 | SANOFI US SERVICES INC. | — | — | Cash or cash equivalent | $60.00 | Research |
| Study: A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | ||||||
| 03/21/2024 | SANOFI US SERVICES INC. | — | — | Cash or cash equivalent | $20.10 | Research |
| Study: A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | ||||||
| 03/09/2024 | SANOFI US SERVICES INC. | — | — | In-kind items and services | $1,110.01 | Research |
| Study: A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | ||||||
| 03/09/2024 | SANOFI US SERVICES INC. | — | — | In-kind items and services | $661.82 | Research |
| Study: A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | ||||||
| 03/09/2024 | SANOFI US SERVICES INC. | — | — | In-kind items and services | $284.99 | Research |
| Study: A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | ||||||
| 03/09/2024 | SANOFI US SERVICES INC. | — | — | In-kind items and services | $84.99 | Research |
| Study: A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | ||||||
| 03/09/2024 | SANOFI US SERVICES INC. | — | — | In-kind items and services | $75.00 | Research |
| Study: A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | ||||||
| 03/09/2024 | SANOFI US SERVICES INC. | — | — | In-kind items and services | $34.00 | Research |
| Study: A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | ||||||
| 03/09/2024 | SANOFI US SERVICES INC. | — | — | In-kind items and services | $3.68 | Research |
| Study: A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | SANOFI US SERVICES INC. | $2,788 | 16 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 224 | 319 | $125,392 | $35,177 |
| 2022 | 2 | 102 | 164 | $83,097 | $16,172 |
| 2021 | 3 | 110 | 168 | $82,900 | $18,576 |
| 2020 | 2 | 66 | 96 | $33,404 | $6,991 |
Total Patients
502
Total Services
747
Medicare Billing
$76,916
Procedure Codes
10
All Medicare Procedures & Services
10 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 99 | 177 | $84,267 | $22,009 | 26.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 69 | 69 | $22,072 | $11,286 | 51.1% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2023 | 56 | 73 | $19,053 | $1,882 | 9.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 69 | 119 | $71,352 | $14,880 | 20.9% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2022 | 33 | 45 | $11,745 | $1,292 | 11.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 70 | 120 | $66,720 | $15,165 | 22.7% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 14 | 14 | $7,306 | $2,400 | 32.9% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2021 | 26 | 34 | $8,874 | $1,011 | 11.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 39 | 63 | $23,314 | $4,127 | 17.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 27 | 33 | $10,090 | $2,864 | 28.4% |
About Dr. Christopher Lock, MD
Dr. Christopher Lock, MD is a Clinical Neurophysiology healthcare provider based in Stanford, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/26/2008. The National Provider Identifier (NPI) number assigned to this provider is 1427205061.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Christopher Lock, MD has received a total of $260,479 in payments from pharmaceutical and medical device companies, with $23,412 received in 2024. These payments were reported across 309 transactions from 16 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($156,938).
As a Medicare-enrolled provider, Lock has provided services to 502 Medicare beneficiaries, totaling 747 services with total Medicare billing of $76,916. Data is available for 4 years (2020–2023), covering 10 distinct procedure/service records.
Ad
Practice Information
- Specialty Clinical Neurophysiology
- Other Specialties Neurology
- Location Stanford, CA
- Active Since 08/26/2008
- Last Updated 11/10/2023
- Taxonomy Code 2084N0600X
- Entity Type Individual
- NPI Number 1427205061
Products in Payments
- TECFIDERA (Drug) $74,700
- TYSABRI (Biological) $33,070
- AUBAGIO (Drug) $25,738
- LEMTRADA (Drug) $23,454
- Rebif (Biological) $14,968
- ZEPOSIA (Drug) $13,002
- UPLIZNA (Biological) $9,220
- Ozanimod (Drug) $8,054
- Mavenclad (Biological) $7,557
- DISEASE STATE (Drug) $3,985
- UPLIZNA (Drug) $2,073
- OCREVUS (Biological) $1,260
- Mavenclad (Drug) $868.66
- GILENYA (Drug) $582.49
- ARZERRA (Drug) $171.34
- SOLIRIS (Drug) $126.73
- Aimovig (Biological) $122.00
- LEMTRADA (Biological) $90.99
- MAYZENT (Drug) $26.73
- ACTIVA (Device) $20.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Clinical Neurophysiology Doctors in Stanford
Robert Fisher, Md, MD
Clinical Neurophysiology — Payments: $55,386
Clinical Neurophysiology $55,386
Yuen So, Md, MD
Clinical Neurophysiology — Payments: $7,053
Clinical Neurophysiology $7,053
Fanglin Zhang, Md, Phd, MD, PHD
Clinical Neurophysiology — Payments: $1,415
Clinical Neurophysiology $1,415
Viet Nguyen, Md, MD
Clinical Neurophysiology — Payments: $520.59
Clinical Neurophysiology $520.59
Shawn Barton, Md, Phd, MD, PHD
Clinical Neurophysiology — Payments: $35.36
Clinical Neurophysiology $35.36
Scheherazade Le, Md, MD
Clinical Neurophysiology
Clinical Neurophysiology